摘要
目的:观察丹参酮ⅡA对心肾综合征患者血浆IL-6、TNF-α、CRP等炎症因子水平的影响。方法:对入选的28例心肾综合征患者随机分为两组:标准治疗组(标准抗心衰治疗+多巴胺改善肾脏血供)和联合治疗组(标准治疗组治疗方法+丹参酮ⅡA)。观察两组治疗对血浆CRP、IL-6、TNF-α水平等炎症因子水平的影响。结果:与标准治疗组相比,丹参酮ⅡA治疗组血浆CRP、IL-6、TNF-α水平明显减低,并达到显著性差异(CRP:7.89±9.6 vs 13.1±8.6,P<0.05;TNF-:α1.89±1.98 vs 3.15±1.49,P<0.05;IL-6:3.03±3.64 vs 4.96±3.93,P<0.05)。结论:丹参酮ⅡA用于心肾综合征患者的治疗,可改善其全身炎症状态,降低血浆炎性因子水平,可能在提高治疗效果上起到一定作用。
Objective ： To observe the effect of sodium tanshinone IIA sulfonate on the level of serum inflammatory factor, interleukin- 6 （ IL- 6 ） , tumor necrosis factor- alpha （ TNF - α ） and C - reactive protein （CRP） in cardiorenal syndrome patients. Method： 28 patients who were accepting standard heart failure therapy according to ACC/AHA and HFSA Heart Failure Practice Guideline and diagnosed as cardiorenal Syndrome（CRS） ,was divided into two groups randomly, dopamine treatment group and dopamine combined with sodium tanshinone IIA sulfonate treatment group （ combined treatment group ）. The glomerular filtration rate, the level of serum IL-6, TNF-ot and CRP was estimated in each group on 7th day after treatment. Resuit： Contrasted with dopamine treatment group, the levels of serum CRP,TNF-α,IL-6 were decreased significantly in combined treatment group I CRP：7.89 ± 9.6 vs 13.1± 8.6, P〈0. 05 ;TNF-α ： 1.89 ±1.98 vs 3.15 ± 1.49, P〈0.05 ; IL-6：3.03 ± 3.64 vs 4.96 ± 3.93, P〈0.05 ）. Conclusion： Sodium tanshinone IIA sulfonate can relieve the systemic inflammatorome,may improve the short term prognosis by antiinflammatory action in cardiorenal syndrome patients.
出处
《河北医学》
CAS
2011年第4期439-440,共2页
Hebei Medicine
基金
广东省中药管理局科研项目
关键词
心肾综合征
丹参酮ⅡA
炎症因子
Cardiorenal syndrome
Sodium tanshinone IIA sulfonate
Inflammatory factor
